AstaZine is the world’s first astaxanthin extracted from certified organic Haematococcus pluvialis microalgae. AstaZine is produced in a 100 percent, glass tube photobioreactor (PBR) closed system on the world’s second-largest natural astaxanthin farm.
The claims that were approved include statements regarding the health of eyes, the brain and central nervous system, skin, joints, tendons and muscles, and the cardiovascular system. Other approved claims involve supporting healthy DNA and aging, the immune system, and recovery from exercise; improving athletic performance; fighting inflammation; and serving as a powerful antioxidant.
“We’ve been working for months to attain this landmark achievement which now makes us the leader in this critical marketing category,” said Bob Capelli, executive vice president of global marketing for Algae Life Sciences. “We have some extremely compelling claims that are now allowed for AstaZine. This will enable brands to successfully market Astaxanthin with an incredible variety of health claims. Individual brands can customize their message to consumers while educating about astaxanthin’s extensive clinically validated health benefits.”
Chief Operating Officer Lixin Ding, Ph.D., added, “Astaxanthin has been validated in approximately 500 different medical research studies to positively affect eye and brain health, improve skin appearance and quality, support joints and tendons, promote cardiovascular health, and provide various benefits for athletes and active people. And now with 239 allowed claims for labels and marketing literature, brands will easily and legally be able to tell U.S. consumers just how beneficial astaxanthin really is.”
AlgaeLife produces AstaZine in a variety of forms, including 5 percent powder; 5 percent, 10 percent and 20 percent oleoresin; 2 percent water-soluble powder; and 2.0 percent and 2.5 percent microencapsulated beadlets.